Amazon Explores AI Content Marketplace With Media Publishers 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
NEW YORK, March 13, 2018 -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c., President and Chief Executive Officer of SELLAS, will present a corporate overview at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 1:35 p.m. ET in New York, NY.
A live audio webcast of the presentation will be available under “Events & Presentations” in the Investors section of SELLAS’ website at www.sellaslifesciences.com/investors. A replay of the webcast will be available for up to 30 days on SELLAS’ website following the presentation.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS has Phase 3 clinical trials planned (pending funding availability) for GPS in two indications, acute myeloid leukemia (AML) and malignant pleural mesotheliomia (MPM) and is also developing GPS as a potential treatment for multiple myeloma and ovarian cancer. SELLAS plans to study GPS in up to four additional indications. SELLAS has received Orphan Drug designations from the U.S. Food & Drug Administration (FDA), as well as the European Medicines Agency, for GPS in AML and MPM; GPS also received Fast Track designation for AML and MPM from the FDA.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Investor Contact:
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]
David Moser, JD
SELLAS Life Sciences Group, Inc.
813-864-2571
[email protected]
Source: SELLAS Life Sciences Group, Inc.
